Apellis and Sobi’s Empaveli yields positive Phase III data in PNH

May 26, 2021 (Last Updated May 26th, 2021 12:22)

Apellis and Sobi’s Phase III PRINCE trial of Empaveli meets primary endpoints in paroxysmal nocturnal haemoglobinuria patients.

Apellis and Sobi’s Empaveli yields positive Phase III data in PNH
A rare blood disorder, paroxysmal nocturnal haemoglobinuria is caused by loss red blood cells that carry oxygen. Credit: allinonemovie from Pixabay.

Apellis Pharmaceuticals and Swedish Orphan Biovitrum (Sobi) have reported positive top-line data from the Phase III PRINCE clinical trial of Empaveli (pegcetacoplan) in treatment naïve paroxysmal nocturnal haemoglobinuria (PNH) patients.

A rare blood disorder, PNH is caused by the loss of red blood cells that carry oxygen, due to extravascular and intravascular haemolysis.

Over time, low haemoglobin can cause debilitating symptoms such as severe fatigue, haemoglobinuria, and difficulty breathing.

Empaveli is the first therapy with approval to target C3, the vital protein in the complement cascade. The drug’s proximal action in the complement cascade regulates C3b-mediated extravascular haemolysis and terminal complement-mediated intravascular haemolysis.

In the US, the drug holds approval to treat PNH in adults.

The randomised, multi-centre, open-label PRINCE trial assessed the drug in 53 patients who did not receive a complement inhibitor within three months prior to the trial screening.

In the 26-week randomised, controlled period, participants were given 1,080mg Empaveli twice weekly or standard of care therapy, excluding complement inhibitors.

The Phase III trial’s primary objective was the efficacy and safety of the drug.

Compared to the standard of care, Empaveli showed statistical superiority on the co-primary endpoints of haemoglobin stabilisation and lactate dehydrogenase (LDH) decrease at week 26.

According to the top-line results, 86% of subjects on the drug demonstrated haemoglobin stabilisation versus 0% on the standard of care.

Empaveli led to a 90% reduction in mean LDH from baseline compared to 14% with standard of care therapy.

In addition, the drug demonstrated statistical superiority on various secondary endpoints, including improvements in haemoglobin levels and eliminating the need for transfusion, compared to standard of care.

The drug’s safety profile was observed to be consistent with prior data and the most common adverse events were injection site reaction, hypokalaemia and fever.

Apellis Pharmaceuticals chief medical officer Federico Grossi said: “The positive PRINCE data showed that Empaveli provided clinically meaningful improvements across multiple measures that are important for patients and build on our recent FDA approval of Empaveli in PNH.

“Combined with previous studies, these results emphasize the potential of Empaveli to provide disease control for all adults with PNH regardless of prior treatment.”

The PRINCE trial was performed in alliance with SFJ Pharmaceuticals, which supported the development of the drug in PNH.